Navigation Links
XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
Date:11/14/2009

The FDA is reviewing preliminary safety information on XOLAIR allergic asthma medication. Problems with XOLAIR have been linked to heart attack and stroke. The Onder Law Firm is offering a free case review to those or families of those who may have experienced serious health problems after taking XOLAIR.

St. Louis, MO (Vocus) November 14, 2009 -- The FDA is evaluating interim safety findings from Genentech, Inc. in an ongoing study of XOLAIR problems. XOLAIR (omalizumab) is an injected drug for asthma related allergies. The interim results of this study, which is being conducted by the drug’s manufacturer, suggests an increased number of cardiovascular (heart attack) and cerebrovascular (stroke) adverse events in a group of patients using Xolair compared to a group of patients not given the drug (control group).

The possible association has been identified based on interim results from an ongoing study of Xolair known as Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS). The results this study are not expected until 2012. Although the FDA and the drug manufacturer have not recalled XOLAIR, the FDA wants consumers to be aware of increased risks from taking XOLAIR, specifically heart attack/heart disease and stroke.

The FDA originally approved XOLAIR in 2003 but announced in February of 2007 that it was requesting a stronger warning for XOLAIR because it may cause anaphylaxis, a reaction that may include trouble breathing, chest tightness, dizziness, fainting, itching and hives, and swelling of the mouth and throat.

“It is important for persons who have used or are using XOLAIR to be aware of the side effects and hazards,” stated James Onder of Onder, Shelton, O’Leary & Peterson, LLC. The firm’s XOLAIR safety information web site contains information regarding XOLAIR side effects and the rights those suffering from them may have. The attorneys of The Onder Law Firm will review will provide free case review to persons having experienced side effects or medical problems after taking XOLAIR. The Onder Law Firm provides experienced legal representation without fee unless it collects for its clients.

About The Law Firm
Onder, Shelton, O’Leary & Peterson, LLC is a personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O’Leary & Peterson has represented clients throughout the United States in pharmaceutical litigation such as Vioxx, Digitek, Ethex and others, and other law firms throughout the nation often seek its experience and expertise on complex litigation. For more information, visit www.onderlaw.com or call 1-877-ONDER-LAW.

# # #

Read the full story at http://www.prweb.com/releases/xolair/safety/prweb3207784.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. FDA Investigating Safety of Asthma Drug Xolair
2. FDA Questions Safety of Caffeinated Alcoholic Drinks
3. Centerplate and the Capital Improvement Board Investigating Food Safety Violations at Lucas Oil Stadium to Ensure Highest Standards Achieved and Operational Excellence
4. New Polls, Reports Highlight The Need To Update The U.S. Food Safety System And To Make Our Food Safe For The Holidays
5. New Research Center to Focus on Cardiac Safety and Innovation
6. New research center to focus on cardiac safety and innovation
7. Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety
8. Top Five International Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
9. Capnography Monitoring Significantly Improves Patient Safety during Procedural Sedation in the Emergency Department
10. FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDAs international posts, LASIK eye surgery, and FDA MedWatch safety alerts
11. Dramatic Settlement Sets National Model for H1N1 Hospital Safety Measures
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
(Date:3/29/2017)... Tampa, FL (PRWEB) , ... March 30, 2017 , ... Grass pollen is the main ... sufferers allergic to the stuff. The season for grass pollen runs from May to July ... what’s a hay fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
(Date:3/29/2017)... Indianapolis, IN (PRWEB) , ... March 29, 2017 ... ... Benefits Study, this webinar provides insight into the challenges employers face in trying ... the complexity of managing employee benefits programs? Adding to the growing complexity, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
(Date:3/29/2017)... Optometrists have staunchly strived to deliver ... in quality and care for more than a ... refraction technologies and process to challenge the eyeglass ... level of refraction and correction care standardization of ... Navy fighter pilots, but now available to every ...
(Date:3/29/2017)... 29, 2017 Transparency Market ... provides an exhaustive study of the U.S. substance abuse ... companies are functional in this market at present, ... leading companies, such as GlaxoSmithKline Plc., Pfizer Inc., ... on various marketing strategies to increase their visibility, ...
Breaking Medicine Technology: